CPC
COMPANY PROFILES
AND
CONFERENCES
 
 Welcome Guest

Currency:  Euro Dollor Pound  |  Cart  ( 0 ) items in cart
   
Search
Advanced search
 
BROWSE INDUSTRY


SignUp


Home Back Research Index Back Pharmaceuticals and Healthcare Back Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review

Enquire | Email | Print

 
Format PDF
ISBN GDPH127014FSA
Published Date June 2014
No. of Pages 40
Select pricing :
Change Currency : EURO | $ USD | £ GBP
 
Bookmark and Share
 
Description
 
  • Abstract
  • Table of Contents

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmuPharma plc (ImmuPharma) is a pharmaceutical company. The company focuses on the development of novel drugs to treat serious medical conditions with unmet need. ImmuPharma has five drugs in development stage towards the treatment of lupus, cancer, moderate to severe pain, highly resistant hospital-acquired infections such as MRSA and inflammatory disorders.

Immupharma Plc Key Recent Developments

Jun 16, 2014: ImmuPharma Announces New Optically Pure Compounds for Improved Therapeutic Efficiency
May 21, 2014: ImmuPharma announce preliminary results for the year ended 31 December 2013
Apr 23, 2014: Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan
Sep 27, 2013: Immupharma Announces Interim Results
Jul 08, 2013: Immupharma Appoints Worldwide Key Opinion Leaders to Scientific Advisory Board for Lupuzor Phase III

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Immupharma Plc - Key Facts 6
Immupharma Plc - Key Employees 7
Immupharma Plc - Key Employee Biographies 8
Immupharma Plc - Major Products and Services 9
Immupharma Plc - Pharmaceutical Pipeline Products Data 10
Immupharma Plc, Pipeline Products by Therapy Area 10
Immupharma Plc, Pipeline Products by Development Phase 11
Immupharma Plc - History 13
Immupharma Plc - Company Statement 15
Immupharma Plc - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 17
Immupharma Plc - Business Description 17
Immupharma Plc - Corporate Strategy 18
Immupharma Plc - SWOT Analysis 19
SWOT Analysis - Overview 19
Immupharma Plc - Strengths 19
Strength - Lead Product Candidate - Lupuzor 19
Strength - Patent Portfolio 19
Strength - Agreements and Collaborations 19
Immupharma Plc - Weaknesses 19
Weakness - Reliance on Third-Parties 19
Weakness - Lack of Marketed Products 20
Immupharma Plc - Opportunities 20
Opportunity - Strong Product Pipeline 20
Opportunity - Market Potential: Cancer 20
Opportunity - Market Potential of Niche Therapeutic Areas 20
Immupharma Plc - Threats 21
Threat - Growing Parallel Trade - EU 21
Threat - Intense Competition 21
Threat - Uncertain R&D Outcomes 21
Immupharma Plc - Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios - Interim Ratios 27
Financial Ratios - Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 29
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 30
Immupharma Plc, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Jun 16, 2014: ImmuPharma Announces New Optically Pure Compounds for Improved Therapeutic Efficiency 32
May 21, 2014: ImmuPharma announce preliminary results for the year ended 31 December 2013 32
Apr 23, 2014: Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan 33
Sep 27, 2013: Immupharma Announces Interim Results 34
Jul 08, 2013: Immupharma Appoints Worldwide Key Opinion Leaders to Scientific Advisory Board for Lupuzor Phase III 34
Section 6 – Appendix 36
Methodology 36
Ratio Definitions 36
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables

Immupharma Plc, Key Facts 6
Immupharma Plc, Key Employees 7
Immupharma Plc, Key Employee Biographies 8
Immupharma Plc, Major Products and Services 9
Immupharma Plc, Number of Pipeline Products by Therapy Area 10
Immupharma Plc, Number of Pipeline Products by Development Stage 11
Immupharma Plc, Pipeline Products By Therapy Area and Development Phase 12
Immupharma Plc, History 13
Immupharma Plc, Subsidiaries 16
Immupharma Plc, Key Competitors 22
Immupharma Plc, Ratios based on current share price 23
Immupharma Plc, Annual Ratios 24
Immupharma Plc, Interim Ratios 27
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 29
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 30
Immupharma Plc, Recent Deals Summary 31
Currency Codes 36
Capital Market Ratios 36
Equity Ratios 37
Profitability Ratios 37
Cost Ratios 38
Liquidity Ratios 38
Leverage Ratios 39
Efficiency Ratios 39

List of Figures

Immupharma Plc, Pipeline Products by Therapy Area 10
Immupharma Plc, Pipeline Products by Development Phase 11
Immupharma Plc, Performance Chart (2009 - 2013) 26
Immupharma Plc, Ratio Charts 28
Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 29
Immupharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 30


Related reports
  

LeMaitre Vascular, Inc. (LMAT) - Financial and Strategic SWOT Analysis Review

  

Synergetics USA, Inc. (SURG) - Financial and Strategic SWOT Analysis Review

  

Nipro Corporation (8086) - Financial and Strategic SWOT Analysis Review

  

Shanghai Kehua Bio-engineering Co., Ltd. (002022) - Financial and Strategic SWOT Analysis Review

  

Moog Inc. (MOG.A) - Financial and Strategic SWOT Analysis Review

  

Positron Corporation (POSC) - Financial and Strategic SWOT Analysis Review

  

Smith & Nephew Plc (SN.) - Financial and Strategic SWOT Analysis Review


Bookmark With : Facebook Blogger MySpace Twitter Del.icio.us Reddit Furl WordProcess
 
Custom Research
If above report does not meet your requirements then you may avail our custom research service. We provide the most comprehensive, affordable, high-quality custom research which will match the exact topic and specifications of your choice. Please visit our Custom Research page to make an enquiry.
 
Product Id : 25486
INR 7695.575
GlobalData
 


RECENTLY VIEWED
 Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review
 
We accept
Master Card Visa
Amex Discover
Paypal Diners Club
Mob +919223375060 / 919223767111
Fax: +91 22 27810778
E-mail:info@companyprofilesandconferences.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST